Until recently the only discriminator was the cancer antigen
125 (CA 125) tumour marker.
A meta-analysis of serum cancer antigen
125 array for diagnosis of ovarian cancer in Chinese.
All these data confirm that the USCN CUZD1 ELISA kit does not recognize the intended antigen, CUZD1, but recognizes and quantifies a known cancer antigen
, CA125, in a similar manner as the well-established and clinically used CA125 kits.
Correlation study of Carcino Embryonic Antigen and Cancer Antigen
This was vastly superior to the 35% positive predictive value in the same samples of cancer antigen
125, the present gold standard clinical biomarker.
RM-1929, a conjugate of Cetuximab and IRDye 700DX, targets epidermal growth factor receptor (EGFR), a cancer antigen
expressed in multiple types of solid tumors.
The need for validating the use of tumor markers was demonstrated in the recent evaluation of cancer antigen
125 (CA125) (2) measurements for monitoring patients with ovarian cancer (2).
In February, the FDA approved an assay for another prostate cancer biomarker, prostate cancer antigen
3 (PCA3), a gene that is specific to prostate cancer and, unlike PSA, is not increased by non-cancerous conditions.
Screening strategies using ultrasound and the cancer antigen
(CA) 125 tumor marker are currently under study and may lower stage at diagnosis but have not yet been shown to change outcomes.
The Risk of Ovarian Malignancy Algorithm (ROMA) stratifies women at high or low risk for epithelial ovarian cancer based on menopausal status and preoperative serum levels of human epididymis protein 4 (HE4) and cancer antigen
125 (CA 125).
Urinary Bcl-2 was more accurate in identifying ovarian cancer than was cancer antigen
125 (CA125), which is currently considered to be the accepted standard for ovarian cancer detection, Dr.
Occasionally, we see a patient with a family history of ovarian cancer who requests a test for cancer antigen
In the study, all participants receiving the Cancer Vac immunotherapy generated immune responses that recognized the MUC 1 cancer antigen
, with the treatment being well tolerated by all patients.
Tokyo, Japan) has patented a tumor antigen gene identified by screening a cDNA library derived from a gastric cancer cell line that can induce gastric cancer antigen
specific cytotoxic T cell by means of hybridization and PCR utilizing an amino acid sequence of peptide fragment of a known gastric cancer antigen
protein, introducing a selected cDNA clone into a cell of gastric cancer cell line that cannot induce gastric cancer antigen
specific cytotoxic T cell so that the clone should be expressed in the cell, and selecting a transgenic cell that has acquired the ability to induce cytotoxic T cell.